WO2011005714A2 - Compositions liposomales de bendamustine - Google Patents

Compositions liposomales de bendamustine Download PDF

Info

Publication number
WO2011005714A2
WO2011005714A2 PCT/US2010/040990 US2010040990W WO2011005714A2 WO 2011005714 A2 WO2011005714 A2 WO 2011005714A2 US 2010040990 W US2010040990 W US 2010040990W WO 2011005714 A2 WO2011005714 A2 WO 2011005714A2
Authority
WO
WIPO (PCT)
Prior art keywords
liposome
bendamustine
composition
siglec
ligand
Prior art date
Application number
PCT/US2010/040990
Other languages
English (en)
Other versions
WO2011005714A3 (fr
Inventor
Alan Saven
Darren Sigal
Original Assignee
Alan Saven
Darren Sigal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alan Saven, Darren Sigal filed Critical Alan Saven
Publication of WO2011005714A2 publication Critical patent/WO2011005714A2/fr
Publication of WO2011005714A3 publication Critical patent/WO2011005714A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Abstract

L'invention porte sur des compositions comprenant un liposome couplé à un ligan de siglec comprenant de la bendamustine, et sur leur utilisation dans le traitement de troubles lymphoprolifératifs des lymphocytes B et sur des compositions comprenant des liposomes non ciblés comprenant de la bendamustine, et sur leur utilisation dans le traitement de troubles lymphoprolifératifs des lymphocytes B et de tumeurs solides.
PCT/US2010/040990 2009-07-07 2010-07-02 Compositions liposomales de bendamustine WO2011005714A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27033009P 2009-07-07 2009-07-07
US61/270,330 2009-07-07
US23890709P 2009-09-01 2009-09-01
US61/238,907 2009-09-01

Publications (2)

Publication Number Publication Date
WO2011005714A2 true WO2011005714A2 (fr) 2011-01-13
WO2011005714A3 WO2011005714A3 (fr) 2011-05-26

Family

ID=43429800

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/040990 WO2011005714A2 (fr) 2009-07-07 2010-07-02 Compositions liposomales de bendamustine

Country Status (1)

Country Link
WO (1) WO2011005714A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1655038A1 (fr) * 2003-08-01 2006-05-10 National Institute of Advanced Industrial Science and Technology Liposome dirige sur une cible, enterique et a absorption commandee possedant une chaine de sucre, ainsi que remede contre le cancer contenant ce liposome et diagnostic mettant en oeuvre ce liposome
US20060193906A1 (en) * 2002-01-30 2006-08-31 National Institute Of Advanced Industrial Science And Technology Sugar-modified liposome and products comprising the liposome
US20070286896A1 (en) * 2003-08-01 2007-12-13 National Institute Of Advanced Industrial Science And Technology Therapeutic or Diagnostic Drug for Inflammatory Disease Comprising Targeting Liposome
US20080193511A1 (en) * 2004-12-23 2008-08-14 Ulrich Massing Manufacture of Lipid-Based Nanoparticles Using a Dual Asymmetric Centrifuge

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060193906A1 (en) * 2002-01-30 2006-08-31 National Institute Of Advanced Industrial Science And Technology Sugar-modified liposome and products comprising the liposome
EP1655038A1 (fr) * 2003-08-01 2006-05-10 National Institute of Advanced Industrial Science and Technology Liposome dirige sur une cible, enterique et a absorption commandee possedant une chaine de sucre, ainsi que remede contre le cancer contenant ce liposome et diagnostic mettant en oeuvre ce liposome
US20070286896A1 (en) * 2003-08-01 2007-12-13 National Institute Of Advanced Industrial Science And Technology Therapeutic or Diagnostic Drug for Inflammatory Disease Comprising Targeting Liposome
US20080193511A1 (en) * 2004-12-23 2008-08-14 Ulrich Massing Manufacture of Lipid-Based Nanoparticles Using a Dual Asymmetric Centrifuge

Also Published As

Publication number Publication date
WO2011005714A3 (fr) 2011-05-26

Similar Documents

Publication Publication Date Title
Koudelka et al. Liposomal paclitaxel formulations
Maruyama Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects
JP5438317B2 (ja) 新規リポソーム組成物
JP3415131B1 (ja) リポソーム製剤
Peer et al. Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal doxorubicin in syngeneic and human xenograft mouse tumor models
Straubinger et al. Novel Taxol formulations: Taxol-containing liposomes.
Liu et al. Application of liposomal technologies for delivery of platinum analogs in oncology
Tamam et al. Development of liposomal gemcitabine with high drug loading capacity
KR101309440B1 (ko) 옥살리플라틴 리포솜 제제를 함유하는 항종양효과 증강제 및 상기 리포솜 제제를 함유하는 항종양제
Allahou et al. Investigating the application of liposomes as drug delivery systems for the diagnosis and treatment of cancer
JP2006513984A (ja) 医薬的に活性な、脂質をベースにしたｓｎ３８製剤
EP2190411A2 (fr) Compositions à base de liposomes pour une administration in vivo de composés d'acide boronique
US20040022842A1 (en) Liposome preparations containing oxaliplatin
US20090092662A1 (en) Liposome formulations of boronic acid compounds
Nik et al. Targeted‐nanoliposomal combretastatin A4 (CA‐4) as an efficient antivascular candidate in the metastatic cancer treatment
Gaber Modulation of doxorubicin resistance in multidrug-resistance cells by targeted liposomes combined with hyperthermia.
Hu et al. Treatment of lung cancer by peptide-modified liposomal irinotecan endowed with tumor penetration and NF-κB inhibitory activities
US20100166843A1 (en) Pharmaceutical composition comprising a campothecin derivative
US20110268653A1 (en) Compositions and Methods Related to Acid Stable Lipid Nanospheres
Kawano et al. Antitumor efficacy and biodistribution of liposomal sepantronium bromide (YM155), a novel small-molecule survivin suppressant
Arantseva et al. Platinum-Based Antitumor Drugs and Their Liposomal Formulations in Clinical Trials
WO2011005714A2 (fr) Compositions liposomales de bendamustine
Zhao et al. A study of liposomal formulations to improve the delivery of aquated cisplatin to a multidrug resistant tumor
US20230068750A1 (en) Methods & Systems for Controlled Release of Drug Cargo via ATP- Responsive Liposomes
Bryde et al. Nanocapsules of platinum anticancer drugs: development towards therapeutic use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10797689

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10797689

Country of ref document: EP

Kind code of ref document: A2